ACTG 372 - A Phase II Study of the Prolongation of Virologic Success and Options for Virologic Failure in HIV-Infected Subjects Receiving Indinavir in Combination with Nucleoside Analogs: A Rollover Study for ACTG 320. The purpose of this study is 1) to determine how many people will have an undetectable amount of plasma HIV (less than 500 copies/ml) by week 16; 2) to determine the length of time that plasma HIV levels remain less than 500 copies/ml; and 3) to establish if these drugs are safe to take in combination and how well they are tolerated. This study will use zidovudine (ZDV), stavudine (d4T), lamivudine (3TC), didanosine (ddl), nelfinavir (NFV), abacavir (1592U89), adefovir dipivoxil, L-carnitine, efavirenz (DMP-266), and indinavir. Indinavir, nelfinavir, and abacavir (1592U89) are FDA approved protease inhibitors. Efavirenz (DMP-266) is an FDA approved anit-HIV drug. Adefovir dipivoxil is still considered investigational. Early studies have shown that these drugs may be helpful in preventing HIV from multiplying in the body. In order to be screened for participation in this study, the individual must be taking ZDV (or d4T) and 3TC with indinavir (IDV) for at least three months prior to and up to the time of the study. The individuals HIV RNA level (amount of HIV in the blood) must be more than 500 copies/mL. All study drugs will be given by mouth. Approximately 440 subjects will be recruited at multiple sites.

Project Start
1999-12-01
Project End
2000-11-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
39
Fiscal Year
2000
Total Cost
$32,212
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Hayden, Kathleen M; Baker, Laura D; Bray, George et al. (2018) Long-term impact of intensive lifestyle intervention on cognitive function assessed with the National Institutes of Health Toolbox: The Look AHEAD study. Alzheimers Dement (Amst) 10:41-48
Shah, V N; Sippl, R; Joshee, P et al. (2018) Trabecular bone quality is lower in adults with type 1 diabetes and is negatively associated with insulin resistance. Osteoporos Int 29:733-739
Jensen, Thomas; Bjornstad, Petter; Johnson, Richard J et al. (2018) Copeptin and Estimated Insulin Sensitivity in Adults With and Without Type 1 Diabetes: The CACTI Study. Can J Diabetes :
Dad, Taimur; Abebe, Kaleab Z; Bae, K Ty et al. (2018) Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease. Kidney Int Rep 3:619-624
Millstein, Richard J; Pyle, Laura L; Bergman, Bryan C et al. (2018) Sex-specific differences in insulin resistance in type 1 diabetes: The CACTI cohort. J Diabetes Complications 32:418-423
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Nowak, Kristen L; You, Zhiying; Gitomer, Berenice et al. (2018) Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol 29:571-578
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187

Showing the most recent 10 out of 1065 publications